Effect of thalidomide and arsenic trioxide on the release of tumor necrosis factor-α and vascular endothelial growth factor from the KG-1a human acute myelogenous leukemia cell line

Girgis,Erian H.; Mahoney,John P.; Khalil,Rafaat H.; Soliman,Magdi R.

doi:10.3892/ol_00000116

Effect of thalidomide and arsenic trioxide on the release of tumor necrosis factor-α and vascular endothelial growth factor from the KG-1a human acute myelogenous leukemia cell line

Authors:
- Erian H. Girgis
- John P. Mahoney
- Rafaat H. Khalil
- Magdi R. Soliman
View Affiliations

Affiliations: College of Pharmacy, Florida A and M University, Tallahassee, FL 32307, USA. erian1.girgis@famu.edu
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000116
Pages: 663-667

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Studies conducted in our lab have indicated that thalidomide cytotoxicity in the KG-1a human acute myelogenous leukemia (AML) cell line was enhanced by combining it with arsenic trioxide. The current investigation was conducted in order to evaluate the effect of thalidomide either alone or in combination with arsenic trioxide on the release of tumor necrosis factor-α (TNF-α) and vascular endothelial growth factor (VEGF) from this cell line in an attempt to clarify its possible cytotoxic mechanism(s). Human AML cell line KG-1a was used in this study. The cells were cultured for 48 h in the presence or absence of thalidomide (5 mg/l), and or arsenic trioxide (4 µΜ). The levels of TNF-α and VEGF in the supernatant were determined by ELISA. Results obtained indicate that the levels of TNF-α in the supernatant of KG-1a cell cultures incubated with thalidomide, arsenic trioxide, or combination were statistically lower than those observed in the supernatant of control cells (2.89, 5.07, 4.15 and 16.88 pg/ml, respectively). However, the levels of VEGF in the supernatant of thalidomide-treated cells were statistically higher than those in the supernatant of control cells (69.61 vs. 11.48 pg/l). Arsenic trioxide, whether alone or in combination with thalidomide, did not produce any statistically significant difference in the levels of VEGF as compared to the control or thalidomide-treated cell supernatant. These findings indicate that thalidomide and the arsenic trioxide inhibition of TNF-α production by KG-1a cells may play an important role in their cytotoxic effect.

View Figures

View References

1	McGeehan GM and Uhl J: TNF-α in human diseases. Curr Pharm Des. 2:662–667. 1996.
2	Snoeck HW, Weekx S, Moulijn A, et al: Tumor necrosis factor alpha is a potent synergistic factor for the proliferation of primitive human hematopoietic progenitor cells and induces resistance to transforming growth factor beta but not to interferon gamma. J Exp Med. 183:705–710. 1996. View Article : Google Scholar
3	Girardin E, Grau GE, Dayer JM, Roux-Lombard P and Lambert PH: Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Eng J Med. 319:397–400. 1988. View Article : Google Scholar : PubMed/NCBI
4	Tracey KJ, Wei H, Manogue KR, et al: Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation. J Exp Med. 167:1211–1227. 1988. View Article : Google Scholar : PubMed/NCBI
5	Sampaio EP, Sarno EN, Galilly R, Cohn ZA and Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 173:699–703. 1991. View Article : Google Scholar
6	Minchinton AL, Fryer KH, Wendt KR, Clow KA and Hayes MM: The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs. 7:339–343. 1996. View Article : Google Scholar : PubMed/NCBI
7	Kruse FF, Joussen AM, Rohrschneider K, Becker MD and Volcker HE: Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 236:461–466. 1998. View Article : Google Scholar : PubMed/NCBI
8	D’Amato RJ, Loughnan MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:4082–4085. 1994.
9	Lu C and Hassan HT: Human stem cell factor-antibody (anti-SCF) enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukemia cells. Leuk Res. 30:296–302. 2006.PubMed/NCBI
10	Renauld AE and Spengler RN: Tumor necrosis factor expressed by primary hippocampal neurons and SH-SY5Y cells is regulated by α2-adrenergic receptor activation. J Neurosci Res. 67:264–274. 2001.PubMed/NCBI
11	Ogasawara T, Narita C and Kawauchi K: Production of vascular endothelial growth factor in T-cell prolymphocytic leukemia. Leuk Res. 31:403–406. 2007. View Article : Google Scholar : PubMed/NCBI
12	Folkman J: Angiogenesis: mechanistic insights, neovascular diseases in cancer, rheumatoid and other disease. Nature Med. 1:27–31. 1995. View Article : Google Scholar
13	Aguayo A, Estey E, Kantarjian H, et al: Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 94:3717–3721. 1999.PubMed/NCBI
14	Fiedler W, Graeven U, Ergun S, et al: Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 89:1870–1875. 1997.PubMed/NCBI
15	Koch HP: Thalidomide and congeners as anti-inflammatory agents. Prog Med Chem. 22:165–242. 1985. View Article : Google Scholar : PubMed/NCBI
16	Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA and Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 177:1675–1680. 1993. View Article : Google Scholar : PubMed/NCBI
17	Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM and Sarno EN: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 168:408–414. 1993. View Article : Google Scholar : PubMed/NCBI
18	Shannon EJ, Morales MJ and Sandoval F: Immunomodulatory assays to study structure-activity relationships of thalidomide. Immunopharmacology. 35:203–212. 1997. View Article : Google Scholar : PubMed/NCBI
19	Tavares JL, Wangoo A, Dilworth P, Marshall B, Kotecha S and Shaw RJ: Thalidomide reduces tumor necrosis factor alpha production by human alveolar macrophages. Respir Med. 91:31–39. 1997. View Article : Google Scholar : PubMed/NCBI
20	Brieger J, Schroeder P, Gosepath J and Mann WJ: Vascular endothelial growth factor and basic fibroblast growth factor are released by squamous cell carcinoma cells after irradiation and increase resistance to subsequent irradiation. Intl J Mol Med. 16:159–164. 2005.
21	Shintani S, Kiyota A, Mihara M, Nakahara Y, Terakado N, Ueyama Y and Matsumura T: Association of preoperative radiation effect with tumor angiogenesis and vascular endothelial growth factor in oral squamous cell carcinoma. Jpn J Cancer. 91:1051–1057. 2000. View Article : Google Scholar : PubMed/NCBI
22	Koukourakis MI, Giatromanolaki A, Sirvidis E, Simopoulos K, Pissakas G, Gatter KC and Harris AL: Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy. Anticancer Res. 2:4301–4309. 2001.PubMed/NCBI
23	Geng L, Donnelly E, McMahon G, Lin PC, Sierra-River E, Oshinka H and Hallahan DE: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61:2413–2419. 2001.PubMed/NCBI